US 10238749
Angiotensinogen (AGT) iRNA compositions and methods of use thereof
granted A61KA61K45/06A61K47/549
Quick answer
US patent 10238749 (Angiotensinogen (AGT) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 44
- CPC classes
- A61K, A61K45/06, A61K47/549, A61P, A61P11/00